Xeris Biopharma
Xeris Biopharma works on 1 rare disease tracked on Trial Friend, including Cushing Disease, with 1 FDA-approved rare disease drug.
Xeris Biopharma is a Chicago-based specialty pharmaceutical company founded in 2005, known for its ready-to-use injectable formulation technology. Its rare disease products include Recorlev (levoketoconazole) for endogenous Cushing syndrome and Keveyis (dichlorphenamide) for primary periodic paralysis, both gained through the 2021 merger with Strongbridge Biopharma. The company also markets Gvoke, a ready-to-use glucagon for severe hypoglycemia. Recorlev ended 2025 with roughly 700 patients on therapy.
Active Clinical Trials
Xeris Biopharma FDA-Approved Drugs (1)
Medications developed or marketed by Xeris Biopharma that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| LEVOKETOCONAZOLE Cortisol Synthesis Inhibitor [EPC] | Recorlev oral | — | Dec 30, 2021 |
Rare Disease Focus Areas (1)
Diseases targeted by Xeris Biopharma's clinical trial and drug development programs
Patient Resources
Organizations and resources related to Xeris Biopharma's rare disease focus areas
Frequently Asked Questions About Xeris Biopharma
Common questions about Xeris Biopharma's rare disease programs, clinical trials, and treatments.